drugset / Trial / NCT05609812

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

NCT05609812

Phase 3 Withdrawn Vera Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.

Timeline

Start
2022-11-02
Primary completion
2026-03-15
Completion
2028-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Atacicept Protein / enzyme biologic Subcutaneous

Indications